Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

307 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Novel STAT 3 inhibitors for treating gastric cancer.
Cafferkey C, Chau I. Cafferkey C, et al. Expert Opin Investig Drugs. 2016 Sep;25(9):1023-31. doi: 10.1080/13543784.2016.1195807. Epub 2016 Jun 20. Expert Opin Investig Drugs. 2016. PMID: 27322026 Review.
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A. Chau I, et al. Br J Cancer. 2001 Nov 2;85(9):1258-64. doi: 10.1054/bjoc.2001.2036. Br J Cancer. 2001. PMID: 11720458 Free PMC article. Clinical Trial.
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M. Maisey N, et al. J Clin Oncol. 2002 Jul 15;20(14):3130-6. doi: 10.1200/JCO.2002.09.029. J Clin Oncol. 2002. PMID: 12118027 Clinical Trial.
Chemotherapy in colorectal cancer: new options and new challenges.
Chau I, Cunningham D. Chau I, et al. Br Med Bull. 2002;64:159-80. doi: 10.1093/bmb/64.1.159. Br Med Bull. 2002. PMID: 12421732 Review.
Adjuvant therapy in colon cancer: current status and future directions.
Chau I, Cunningham D. Chau I, et al. Cancer Treat Rev. 2002 Oct;28(5):223-36. doi: 10.1016/s0305-7372(02)00047-6. Cancer Treat Rev. 2002. PMID: 12435370 Review.
Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies.
Chau I, Rigg A, Cunningham D. Chau I, et al. Crit Rev Oncol Hematol. 2003 Feb;45(2):151-76. doi: 10.1016/s1040-8428(02)00015-x. Crit Rev Oncol Hematol. 2003. PMID: 12604127 Review.
Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.
Chau I, Allen M, Cunningham D, Tait D, Brown G, Hill M, Sumpter K, Rhodes A, Wotherspoon A, Norman AR, Hill A, Massey A, Prior Y. Chau I, et al. Br J Cancer. 2003 Apr 7;88(7):1017-24. doi: 10.1038/sj.bjc.6600822. Br J Cancer. 2003. PMID: 12671697 Free PMC article.
Patients received protracted venous infusion 5-FU (300 mg m(-2) day(-1) for 12 weeks) with mitomycin C (MMC) (7 mg m(-2) i.v. bolus every 6 weeks). ...
Patients received protracted venous infusion 5-FU (300 mg m(-2) day(-1) for 12 weeks) with mitomycin C (MMC) (7 mg m(-2) i.v. bolus e …
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross PJ, Oates J. Saini A, et al. Br J Cancer. 2003 Jun 16;88(12):1859-65. doi: 10.1038/sj.bjc.6600995. Br J Cancer. 2003. PMID: 12799627 Free PMC article. Clinical Trial.
A total of 716 patients with curatively resected Dukes' B or C colorectal cancer were randomised to 5-FU/FA (5-FU 425 mg m(-2) i.v. and FA 20 mg m(-2) i.v. bolus days 1-5 every 28 days for 6 months) or to PVI 5-FU alone (300 mg m(-2) day for 12 weeks). ...
A total of 716 patients with curatively resected Dukes' B or C colorectal cancer were randomised to 5-FU/FA (5-FU 425 mg m(-2) i.v. a …
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Yeoh C, Chau I, Cunningham D, Norman AR, Hill M, Ross PJ. Yeoh C, et al. Clin Colorectal Cancer. 2003 Aug;3(2):102-7. doi: 10.3816/CCC.2003.n.016. Clin Colorectal Cancer. 2003. PMID: 12952566
307 results
Jump to page
Feedback